恩弗利西马布改善了系统性血管炎中的内皮功能障碍:血管炎症的模型
A D Booth1, D R W Jayne, R K Kharbanda
1Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK. tonybooth1@yahoo.co.uk
Circulation
|March 24, 2004
概括
在抗中性粒细胞质抗体相关的系统性血管炎 (AASV) 中的系统性炎症与内皮功能障碍有关. 抗瘤坏死因子-α (TNF-α) 治疗有效地逆转这种功能障碍,并减少炎症.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 内皮功能障碍和全身炎症是心血管疾病的关键风险因素.
- 临床炎症和内皮功能障碍之间的关系尚不清楚.
- 抗中性粒细胞质抗体相关的系统性血管炎 (AASV) 作为研究这种联系的模型.
研究的目的:
- 测试AASV炎症与内皮功能障碍相关的假设.
- 为了确定抗瘤坏死因子-α (TNF-α) 治疗是否可以逆转炎症诱导的内皮功能障碍.
主要方法:
- 前臂囊造影用于评估14名AASV患者和21名对照者的内皮功能.
- 内皮功能与疾病活性评分 (BVAS) 和炎症标志物 (CRP,IL-6,TNF-alpha) 相相关.
- 评估了抗TNF-α疗法 (infliximab) 对内皮功能的影响.
主要成果:
- 与对照组相比,AASV患者的前臂血流对乙胆 (ACh) 的反应减少 (P=0.002).
- 没有观察到对酸 (SNP) 的反应有显著差异 (P=0.3).
- 即使单独使用 (P=0.03),因弗利西马布治疗也显著改善了ACh反应 (P=0.004),即便是单独使用 (P=0.03).
结论:
- 系统性血管炎与内皮功能受损有关.
- 抗TNF-α治疗导致AASV的临床缓解和减少炎症.
- 抗TNF-α治疗改善了AASV患者的内皮依赖血管运动反应.
相关概念视频
Inflammatory Response I: Vascular and Cellular
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Inflammatory Response II: Inflammatory Exudate and Tissue Repair
The immune system's inflammatory response destroys the invading pathogen, permitting the tissue to heal. The changes during the cellular and vascular stages allow exudate formation at the site of inflammation. The inflammatory exudate released from the wound has high protein content and a specific gravity above 1.020.
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the exudate's...
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the exudate's...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Acute Inflammation II: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...


